Featured Research

from universities, journals, and other organizations

Enzyme May Hold Key To Successfully Treating Pancreatic Cancer With Targeted Immunotherapy

Date:
December 10, 2008
Source:
Thomas Jefferson University
Summary:
An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy. The enzyme is IDO2.

An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, researchers from Thomas Jefferson University reported at the 2008 Annual Meeting of the Southern Surgical Association.

Previous data show that a protein, indoleamine 2,3-dioxygenase (IDO), is overexpressed in pancreatic ductal adenocarcinomas, according to Jonathan R. Brody, Ph.D., an assistant professor in the Department of Surgery at Jefferson Medical College of Thomas Jefferson University in Philadelphia, and co-director of the Jefferson Center for Pancreas, Biliary and Related Cancers. The center is led by Charles J. Yeo, M.D., Samuel D. Gross Professor and chair of the Department of Surgery, who was also involved with the study.

According to Dr. Brody, IDO is an enzyme that represses the immune system, thus protecting the cancer cells and helping them evade immune detection. The Jefferson researchers and their collaborators from the Lankenau Institute for Medical Research (LIMR) in Wynnewood, Pa., previously reported that the IDO inhibitor D-1-methyl-tryptophan (1-MT), preferentially targets a related protein, IDO2.

"Our data are the first that report expression of the IDO2 protein in malignant pancreatic tissue," Dr. Brody said. "About 75 percent of the patients in our cohort have an active enzyme based on genetic analysis. This puts forth the concept of genotyping patients for the IDO2 enzyme, to identify patients who may respond to a therapeutic strategy including an IDO inhibitor, a potential novel drug for pancreatic cancer."

Dr. Brody and his team, which included George Prendergast, Ph.D., and Richard Metz, Ph.D., from LIMR, sequenced IDO2 in 36 resected pancreatic ductal adenocarcinomas to evaluate how many patients harbor an active enzyme in relation to well-known polymorphisms: R235W and Y359STOP. Presumably, only one functional allele needs to be present in order to have an active IDO2 enzyme.

Nineteen percent of the patients were homozygous wild-type, meaning they had two active alleles, and 42 percent of the patients were heterozygous, meaning they had one active allele. Twenty-five percent were homozygous for two inactive IDO2 alleles. The remaining 14 percent were difficult to determine due to limits in sequencing and distinguishing the alleles, but were most likely heterozygous, according to Dr. Brody.

Phase-1 studies of 1-MT, the IDO inhibitor are currently underway.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Enzyme May Hold Key To Successfully Treating Pancreatic Cancer With Targeted Immunotherapy." ScienceDaily. ScienceDaily, 10 December 2008. <www.sciencedaily.com/releases/2008/12/081201112620.htm>.
Thomas Jefferson University. (2008, December 10). Enzyme May Hold Key To Successfully Treating Pancreatic Cancer With Targeted Immunotherapy. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2008/12/081201112620.htm
Thomas Jefferson University. "Enzyme May Hold Key To Successfully Treating Pancreatic Cancer With Targeted Immunotherapy." ScienceDaily. www.sciencedaily.com/releases/2008/12/081201112620.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins